Indication
Post-Essential Thrombocythemia MF
1 clinical trial
2 products
Clinical trial
A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) Who Are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor TreatmentStatus: Recruiting, Estimated PCD: 2023-12-31
Product
Best Available TherapyProduct
KRT-232